

Claim 13, line 1, change "8" to --16-- and "cells are" to --
cell is a--; and

line 2, change "phagocytes" to --phagocyte--.

Claim 14, line 2, change "phagocytes are" to --phagocyte is
a-- and change "monocytes" to --monocyte--.

Claim 15, line 1, change "8" to --16--.

Add the following new claims.

--16. A method of inhibiting CD44-facilitated HIV infection
of a cell susceptible to HIV infection comprising contacting said
cell with an amount of an anti-CD44 antibody sufficient to bind
to CD44 molecules present on the surface of said cell and thereby
inhibit said CD44-facilitated infection of said cell.

--17. The method according to claim ¹⁶13 wherein said
mononuclear phagocytes are ^{vaginal} mucosal cells.

18. The method according to claim ¹⁶13 wherein said
contacting is effected by topical administration.

19. The method according to claim 16 wherein said cells are
~~ex vivo~~ mononuclear phagocytes.-----

IN THE ABSTRACT:

Substitute the Abstract of the Disclosure submitted herewith
on a separate sheet for that originally filed.

REMARKS

Reconsideration of this application and entry of the
foregoing amendments are respectfully requested.

Applicants hereby affirm the verbal election of the subject
matter of Group I for prosecution in this application. The
Examiner's comments on page 3 of the Action, third paragraph,
regarding the rejoining of the subject matter of Groups II and
III are noted but not understood. Clarification is respectfully
requested.

The title has been revised in accordance with the Examiner's
request.

The specification has been revised to correct errors and
capitalize trademarks. The specification has also been revised
to include Sequence ID numbers and to include a Sequence Listing.
Submitted herewith is a computer-readable copy of that Listing